0001179110-13-005087.txt : 20130313 0001179110-13-005087.hdr.sgml : 20130313 20130313193755 ACCESSION NUMBER: 0001179110-13-005087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130311 FILED AS OF DATE: 20130313 DATE AS OF CHANGE: 20130313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WOOD JULIANNA R CENTRAL INDEX KEY: 0001282660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 13688762 MAIL ADDRESS: STREET 1: 3031 RESEARCH DR STREET 2: BLDG A CITY: RICHMOND STATE: CA ZIP: 84806 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml FORM 4 - X0306 4 2013-03-11 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001282660 WOOD JULIANNA R C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 VP, Public Affairs Common Stock 2013-03-11 4 M 0 820 28.55 A 19039 D Common Stock 2013-03-11 4 M 0 766 30.28 A 19805 D Common Stock 2013-03-11 4 M 0 547 35.18 A 20352 D Common Stock 2013-03-11 4 M 0 1198 37.68 A 21550 D Common Stock 2013-03-11 4 S 0 3331 85.65 D 18219 D Common Stock 200 I Children's Trust Stock Option (Right to Buy) 28.55 2013-03-11 4 M 0 820 0.00 D 2019-03-31 Common Stock 820 2393 D Stock Option (Right to Buy) 30.28 2013-03-11 4 M 0 766 0.00 D 2020-03-31 Common Stock 766 7910 D Stock Option (Right to Buy) 35.18 2013-03-11 4 M 0 547 0.00 D 2021-03-31 Common Stock 547 13307 D Stock Option (Right to Buy) 37.68 2013-03-11 4 M 0 1198 0.00 D 2022-03-29 Common Stock 1198 20364 D Shares sold pursuant to a 10b5-1 plan. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. /s/ Warren DeSouza, Attorney-in-fact 2013-03-12